```
=> d his

     (FILE 'HOME' ENTERED AT 19:52:11 ON 21 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 19:52:22 ON 21 MAR 2009
L1             STRUCTURE UPLOADED
L2               0 S L1
L3              16 S L1 FULL

=> d que l3 stat
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3              16 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED       29 ITERATIONS                                16 ANSWERS
SEARCH TIME: 00.00.01


=> d 1-16 ide can
```

L3 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1022178-87-5 REGISTRY
ED Entered STN: 23 May 2008
CN Propanamide, N-(6-bromo-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H11 Br F3 N O5 S2
SR CA
LC STN Files: CA, CAPLUS



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

L3 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 827629-18-5 REGISTRY
ED Entered STN: 09 Feb 2005
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-e][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)-, mixt. with 5-[(2R)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide monohydrochloride (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H28 N2 O5 S . C16 H12 F3 N O5 S2 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 106463-17-6 (106133-20-4)
CMF C20 H28 N2 O5 S . Cl H

Absolute stereochemistry. Rotation (-).



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:162637

L3 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 827629-17-4 REGISTRY
ED Entered STN: 09 Feb 2005
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-,
4-(diethylamino)-2-butynyl ester, hydrochloride, mixt. with
(2S)-N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-
3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H31 N O3 . C16 H12 F3 N O5 S2 . Cl H
CI MXS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 1508-65-2 (5633-20-5)
CMF C22 H31 N O3 . Cl H




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:162623

L3 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 827629-16-3 REGISTRY
ED Entered STN: 09 Feb 2005
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-e][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)-, mixt. with 2-[(1R)-3-bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C22 H31 N O . C16 H12 F3 N O5 S2 . C4 H6 O6
CI MXS
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 124937-52-6
CMF C22 H31 N O . C4 H6 O6

CM 3

CRN 124937-51-5
CMF C22 H31 N O

Absolute stereochemistry.




CM 4

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:162623

L3 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 332029-03-5 REGISTRY
ED Entered STN: 23 Apr 2001
CN Propanamide, N-(4,10-dihydro-3-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H11 F3 N2 O7 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:261274

L3 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 332029-02-4 REGISTRY
ED Entered STN: 23 Apr 2001
CN Propanamide, N-(4,10-dihydro-2-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H11 F3 N2 O7 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:261274

L3 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-52-0 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-3-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H11 F3 N2 O7 S2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:316211

L3 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-51-9 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-2-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H11 F3 N2 O7 S2
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:316211

L3 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-38-2 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, 3,3,3-trifluoro-N-(6-fluoro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H11 F4 N O5 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

REFERENCE 2: 134:261274

REFERENCE 3: 129:316211

L3 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-36-0 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(6-chloro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H11 Cl F3 N O5 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

REFERENCE 2: 137:289043

REFERENCE 3: 134:261274

REFERENCE 4: 129:316211

L3 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-34-8 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-8-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C17 H14 F3 N O5 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:261274

REFERENCE 2: 129:316211

L3 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-30-4 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-6-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C17 H14 F3 N O5 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

REFERENCE 2: 134:261274

REFERENCE 3: 129:316211

L3 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-29-1 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-6-methoxy-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C17 H14 F3 N O6 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:261274

REFERENCE 2: 129:316211

L3 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-27-9 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H12 F3 N O5 S2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:261274

REFERENCE 2: 129:316211

L3 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214764-26-8 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)
OTHER NAMES:
CN (S)-5,5-Dioxo-9-[(3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino]-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one
CN KW 7158
FS STEREOSEARCH
MF C16 H12 F3 N O5 S2
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, PROUSDDR, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

20 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

REFERENCE 2: 144:212756

REFERENCE 3: 143:83428

REFERENCE 4: 142:212362

REFERENCE 5: 142:170135

REFERENCE 6: 142:168588

REFERENCE 7: 142:162637

REFERENCE 8: 142:162623

REFERENCE 9: 142:120499

REFERENCE 10: 141:325736

L3 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 214763-95-8 REGISTRY
ED Entered STN: 25 Nov 1998
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)
MF C16 H12 F3 N 05 S2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 148:509925

REFERENCE 2: 144:212756

REFERENCE 3: 142:162637

REFERENCE 4: 142:162623

REFERENCE 5: 134:261274

REFERENCE 6: 129:316211

```
=> fil capl
FILE 'CAPLUS' ENTERED AT 19:54:04 ON 21 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Mar 2009  VOL 150 ISS 13
FILE LAST UPDATED: 20 Mar 2009  (20090320/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'.FIONA' IS DEFAULT FORMAT FOR 'CAPLUS' FILE

=> s l3
L4          20 L3

=> d l-20 bib abs hitstr
```

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:529662 CAPLUS
DN 148:509925
TI Therapeutic agents for irritable bowel syndrome
IN Yamagata, Tsuyoshi; Shibata, Kenji; Nishiya, Yoichi; Seishi, Takashi; Sakuma, Takashi
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2008050853 | A1 | 20080502 | WO 2007-JP70881 | 20071026 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| PRAI | JP 2006-291374 | A | 20061026 | | |
| | JP 2006-329436 | A | 20061206 | | |

OS MARPAT 148:509925
G1




I

AB A therapeutic agent for irritable bowel syndrome which contains as an active ingredient a compound having adenosine uptake inhibitory activity; and a therapeutic agent for irritable bowel syndrome which contains as an active ingredient either a tricyclic compound represented by the formula (I) [wherein L represents -NHC(=O)-, etc.; R1 represents hydrogen, halogeno, etc.; X1-X2-X3 represents S-CR7=CR8 (wherein R7 and R8 are the same or different and each represents hydrogen, halogeno, (un)substituted lower alkyl, etc.), etc.; Y represents -CH2SO2-, -SO2CH2-, etc.; and R2 represents (un)substituted lower alkyl, (un)substituted lower alkoxy, (un)substituted aryl, etc.] or a pharmacol. acceptable salt of the compound
IT 214763-95-8P 214764-26-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricylic compds. as therapeutic agents for irritable bowel syndrome)
RN 214763-95-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 214764-30-4 214764-36-0 214764-38-2
1022178-87-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricylic compds. as therapeutic agents for irritable bowel syndrome)
RN 214764-30-4 CAPLUS
CN Propanamide, N-(4,10-dihydro-6-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-36-0 CAPLUS
CN Propanamide, N-(6-chloro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-38-2 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-(6-fluoro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 1022178-87-5 CAPLUS
CN Propanamide, N-(6-bromo-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:116598 CAPLUS
DN 144:212756
TI Process for preparing tricyclic sulfone
IN Imai, Eiichiro; Mimura, Yukiteru; Koizumi, Noriko; Kato, Sachiko; Kinugawa, Masahiko; Sugaya, Toru
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2006013965 | A1 | 20060209 | WO 2005-JP14409 | 20050805 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI JP 2004-231392 | A | 20040806 | | |

OS MARPAT 144:212756
G1




I

AB The title process for producing a tricyclic sulfone represented by the formula I [wherein X represents hydrogen, halogeno, (un)substituted alkyl, mono((un)substituted alkyl)aminocarbonyl, di((un)substituted alkyl)aminocarbonyl, or (un)substituted alkanoylamino; A = SO2], comprises oxidizing a tricyclic sulfide represented by the formula I (X = as defined above; A = S) with potassium hydrogen monopersulfate composite salt (2KHSO5·KHSO4·K2SO4). Tricyclic sulfones are pharmaceuticals or intermediates thereof. Thus, oxidation of (S)-(+)-9-(3,3,3-trifluoro-2-hydroxy-2-methylpropanoylamino)-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one in DMF and water containing Oxone at 35° C for 5 h gave (S)-(+)-5,5-dioxo-9-(3,3,3-trifluoro-2-hydroxy-2-methylpropanoylamino)-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one in 95% yield, vs. 65% yield in the prior art.

IT 214764-26-8P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing tricyclic sulfone by oxidizing tricyclic sulfide with Oxone)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 214763-95-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for preparing tricyclic sulfone by oxidizing tricyclic sulfide with Oxone)
RN 214763-95-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:540584 CAPLUS
DN 143:83428
TI Preparation of microcrystals of dihydrothienobenzothiepinylpropanamide derivative
IN Izawa, Naoto; Satoh, Norie; Yagi, Nobuhiro; Ohuchi, Kazue; Narita, Shoichi; Aoki, Noboru
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005056561 | A1 | 20050623 | WO 2004-JP18773 | 20041209 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004297132 | A1 | 20050623 | AU 2004-297132 | 20041209 |
| CA 2550136 | A1 | 20050623 | CA 2004-2550136 | 20041209 |
| EP 1693374 | A1 | 20060823 | EP 2004-807132 | 20041209 |
| EP 1693374 | B1 | 20081015 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| CN 1845927 | A | 20061011 | CN 2004-80025657 | 20041209 |
| AT 411320 | T | 20081015 | AT 2004-807132 | 20041209 |
| ES 2314484 | T3 | 20090316 | ES 2004-807132 | 20041209 |
| KR 2006121163 | A | 20061128 | KR 2006-711372 | 20060609 |
| US 20070049634 | A1 | 20070301 | US 2006-582328 | 20060609 |
| NO 2006003134 | A | 20060908 | NO 2006-3134 | 20060706 |
| PRAI JP 2003-413725 | A | 20031211 | | |
| WO 2004-JP18773 | W | 20041209 | | |

AB Claimed are microcrystals of (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide (I) with average particle diameter of ≤ 80 μm. I is a known therapeutic agent for urinary incontinence. Crystals of I were pulverized by a jet mill at 0.4 MPa to give microcrystals of I with average particle diameter of 5 μm. Microcrystals of I showed high oral bioavailability and high stability. Capsules containing microcrystals of I were prepared
IT 214764-26-8
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of microcrystals of dihydrothienobenzothiepinylpropanamide derivative with high bioavailability and high stability)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:120727 CAPLUS
DN 142:212362
TI Thienobenzothiepine derivatives as preventive and/or therapeutic agents for bronchial asthma
IN Ikemura, Toshihide; Karasawa, Akira; Ohmori, Kenji
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005011674 | A1 | 20050210 | WO 2004-JP11571 | 20040805 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI JP 2003-205957 | A | 20030805 | | |

OS MARPAT 142:212362
GI



I

AB Preventive and/or therapeutic agents (for bronchial asthma) and tachykinin inhibitors contain I [R1 is hydrogen, halogeno, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower alkoxy; X1-X2-X3 is CR5=CR6-CR7=CR8 (wherein R5, R6, R7 and R8 are each independently hydrogen, substituted or unsubstituted lower alkyl, or the like) or the like; Y is CH2S, CH2SO, CH2SO2, CH2O, etc.; and R2 is hydrogen, substituted or unsubstituted lower alkyl, or the like] or pharmacol. acceptable salts thereof as active ingredients. The bioactivity of (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide (II) was demonstrated. An injectable composition contains II 2 mg, D-mannitol 10 mg, HCl (appropriate amount), aqueous NaOH solution (appropriate amount), distilled water (appropriate amount).

IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thienobenzothiepine derivs. as tachykinin inhibitors or preventive and/or therapeutic agents for bronchial asthma)

RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:76260 CAPLUS
DN 142:162637
TI Medicinal compositions containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide and α1-adrenoceptor blocker
IN Yamagata, Tsuyoshi; Shirakura, Shiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005007155 | A1 | 20050127 | WO 2004-JP10533 | 20040716 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2532806 | A1 | 20050127 | CA 2004-2532806 | 20040716 |
| EP 1649855 | A1 | 20060426 | EP 2004-747897 | 20040716 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| US 20060148885 | A1 | 20060706 | US 2005-562634 | 20051229 |
| PRAI JP 2003-197661 | A | 20030716 | | |
| WO 2004-JP10533 | W | 20040716 | | |

AB It is intended to provide a medicinal composition useful in treating, for example, bladder irritant symptoms accompanying prostate-gland enlargement which comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmacol. acceptable salt thereof and an α1 adrenaline receptor blocker. The effect of combination of (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide and tamsulosin on bladder contraction in bladder hypertrophy rats was examined
IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide and α1-adrenoceptor blocker)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 214763-95-8 827629-18-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide and α1-adrenoceptor blocker)
RN 214763-95-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 827629-18-5 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)-, mixt. with 5-[(2R)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide monohydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 106463-17-6
CMF C20 H28 N2 O5 S . Cl H

Absolute stereochemistry. Rotation (-).



● HCl

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:76259 CAPLUS
DN 142:170135
TI Dihydrothieno[3,2-c][1]benzothiepin-9-ylpropanamide or derivative thereof as preventive and/or therapeutic agent for pain
IN Shirai, Tomomi; Ichikawa, Shunji; Shirakura, Shiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005007154 | A1 | 20050127 | WO 2004-JP10523 | 20040716 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI JP 2003-197694 | A | 20030716 | | |

OS MARPAT 142:170135
AB Claimed is a preventive and/or therapeutic agent for pain containing dihydrothieno[3,2-c][1]benzothiepin-9-ylpropanamide or derivative thereof (Markush structure given) as an active ingredient. (S)-(+)-3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide (I) showed oral analgesic ED50 of 33.1 mg/kg in a mouse test. A formulation for injection contained I 2 mg, D-mannitol 10 mg, HCl (appropriate amount), aqueous NaOH solution (appropriate amount), and distilled water to 2 mL.
IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dihydrothieno[3,2-c][1]benzothiepin-9-ylpropanamide or derivative thereof as preventive and/or therapeutic agent for pain)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:71091 CAPLUS
DN 142:162623
TI Medicinal compositions containing tricyclic heterocyclic compound and anticholinergic agent
IN Yamagata, Tsuyoshi; Shirakura, Shiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005007191 | A1 | 20050127 | WO 2004-JP10521 | 20040716 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2532805 | A1 | 20050127 | CA 2004-2532805 | 20040716 |
| | EP 1652532 | A1 | 20060503 | EP 2004-747885 | 20040716 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | US 20060160887 | A1 | 20060720 | US 2005-562635 | 20051229 |
| PRAI | JP 2003-197662 | A | 20030716 | | |
| | WO 2004-JP10521 | W | 20040716 | | |

AB It is intended to provide a medicinal composition useful in treating, for example, hyperactive bladder which comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmacol. acceptable salt thereof and an anticholine drug. The effect of combination of (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide 0.01 and tolterodine 3 mg/kg on bladder contraction in spinal cord injury rats was examined

IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing tricyclic heterocyclic compound and anticholinergic agent)

RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 214763-95-8 827629-16-3 827629-17-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing tricyclic heterocyclic compound and anticholinergic agent)

RN 214763-95-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 827629-16-3 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)-, mixt. with 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 124937-52-6
CMF C22 H31 N O . C4 H6 O6

CM 3

CRN 124937-51-5
CMF C22 H31 N O

Absolute stereochemistry.




CM 4

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




RN 827629-17-4 CAPLUS
CN Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, 4-(diethylamino)-2-butynyl ester, hydrochloride, mixt. with (2S)-N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (9CI) (CA INDEX NAME)

CM 1

CRN 214764-26-8
CMF C16 H12 F3 N O5 S2

Absolute stereochemistry. Rotation (+).




CM 2

CRN 1508-65-2
CMF C22 H31 N O3 . Cl H



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:14208 CAPLUS
DN 142:120499
TI Therapeutic agents for overactive bladder accompanying cerebrovascular disorder
IN Atsuki, Kaoru; Shirakura, Shiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2005000293 | A1 | 20050106 | WO 2004-JP9363 | 20040625 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI JP 2003-185476 | A | 20030627 | | |

OS MARPAT 142:120499
GI




I




II

AB This invention pertains to a therapeutic agent for overactive bladder accompanying cerebrovascular disorders which contains I [wherein R1 = H, halo, (un)substituted alkyl, or alkoxy; R2 = H, NH2, (un)substituted alkyl, etc.; X1-X2-X3 = (un)substituted CH=CH-CH=CH, N(O)m=CH-CH=CH, CH=CH-O, etc.; m = 0 or 1; Y = CH2S, CH2O, CH=CH, etc.] or pharmaceutically acceptable salts thereof as an active ingredient. For example, compound II was used for the test, and showed pos. results.
IT 214764-26-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; therapeutic agents for overactive bladder accompanying cerebrovascular disorder)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:857378 CAPLUS
DN 141:325736
TI Antitussives
IN Miki, Ichiro; Ishii, Hidee
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2004087131 | A1 | 20041014 | WO 2004-JP4578 | 20040331 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2520680 | A1 | 20041014 | CA 2004-2520680 | 20040331 |
| | EP 1611888 | A1 | 20060104 | EP 2004-724713 | 20040331 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | US 20060205756 | A1 | 20060914 | US 2005-549932 | 20050920 |
| PRAI | JP 2003-94506 | A | 20030331 | | |
| | WO 2004-JP4578 | W | 20040331 | | |

OS MARPAT 141:325736
AB Claimed are antitussives containing thienobenzothiepine derivs. and analogs (Markush structure given) as active ingredients. Thus, the antitussive activity of 2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide was demonstrated. Formulations are given.
IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitussive activity of thienobenzothiepine derivs.)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:816279 CAPLUS
DN 142:168588
TI Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders
AU Gopalakrishnan, Murali; Shieh, Char-Chang
CS Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO Expert Opinion on Therapeutic Targets (2004), 8(5), 437-458
CODEN: EOTTA0; ISSN: 1472-8222
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
AB A review. Potassium channels have re-emerged as attractive targets for overactive bladder and other urol. diseases in recent years, in part due to an enhanced understanding of their mol. heterogeneity, tissue distribution, functional roles and regulation in physiol. and pathol. states. Cloning and heterologous expression anal., coupled with the advancement of improved high-throughput screening techniques, have enabled expeditious identification of selective small-mol. openers and blockers for ATP-sensitive K+ channels, Ca2+-activated K+ channels and voltage-dependent K+ channel-KQT-like subfamily (KCNQ) members, and has paved the way in the assessment of efficacy and adverse effects in preclin. models. This review focuses on the rationale for mol. targeting of K+ channels, the current status of target validation, including preclin. proof-of-concept studies, and provides perspectives on the limitations and hurdles to be overcome in realizing the potential of these targets for diverse urol. indications such as overactive bladder, erectile dysfunction and prostate diseases.
IT 214764-26-8, KW-7158
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KW-7158 is efficacious in suppressing spontaneous bladder activity by inhibiting afferent pathways and possibly opening A-type K+ channel and remains promising approach for further evaluation)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 216 THERE ARE 216 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:547018 CAPLUS
DN 141:64955
TI KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+ currents in neurons of the dorsal root ganglion of the adult rat
AU Sculptoreanu, Adrian; Yoshimura, Naoki; De Groat, William C.
CS Department of Pharmacology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (2004), 310(1), 159-168
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Recent studies revealed that a new compound, KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide], can depress the excitability of afferent pathways from the urinary bladder and reduce bladder overactivity induced by chemical irritation of the urinary tract with xylene, an agent that sensitizes capsaicin-sensitive, C-fiber afferent nerves. In the present expts., we examined the mechanisms that might underlie the depressant effect of KW-7158 on primary afferent neurons by studying the actions of the compound on ion channels and firing in dissociated dorsal root ganglion (DRG) cells from adult rats using whole cell patch-clamp techniques. KW-7158 increased transient, A-type K+ currents at concns. ranging from 50 nM to 1 μM (20-50% increases). Similar effects were seen in fast blue identified bladder afferent neurons. Low concns. of KW-7158 shortened the action potential duration, produced a 5- to 10-mV hyperpolarization, and inhibited repetitive firing induced by either 4-AP (50 μM) or substance P (0.5 μM) in phasic firing DRG neurons. Above 1 μM, KW-7158 elicited a smaller enhancement of A-type K+ currents and in high concns. inhibited the currents. Tetraethylammonium (5-60 mM) and verapamil (50 μM), which block noninactivating K+ currents, did not prevent the facilitatory effects of KW-7158. High concns. of 4-AP (5 mM) inhibited A-type K+ currents and prevented the facilitatory effect of KW-7158 on the remaining currents. These data suggest that KW-7158 enhances A-type K+ currents in DRG neurons. Because A-type K+ channels regulate afferent neuron excitability and firing properties, KW-7158 is a promising new compound for treatment of hyper-reflexic bladder conditions.
IT 214764-26-8, KW-7158
RL: PAC (Pharmacological activity); BIOL (Biological study)
(KW-7158 enhances A-type potassium currents in neurons of dorsal root ganglion of adult rat)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:396713 CAPLUS
DN 138:379274
TI Preventive or remedy for pruritus
IN Hayashi, Ken-ichi; Ichikawa, Shunji; Karasawa, Akira
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2003041704 | A1 | 20030522 | WO 2002-JP11830 | 20021113 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2466790 | A1 | 20030522 | CA 2002-2466790 | 20021113 |
| | AU 2002349539 | A1 | 20030526 | AU 2002-349539 | 20021113 |
| | EP 1444980 | A1 | 20040811 | EP 2002-783557 | 20021113 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | JP 4022519 | B2 | 20071219 | JP 2003-543591 | 20021113 |
| | US 20040248926 | A1 | 20041209 | US 2004-495366 | 20040512 |
| PRAI | JP 2001-347253 | A | 20011113 | | |
| | WO 2002-JP11830 | W | 20021113 | | |

OS MARPAT 138:379274
GI



I

AB A pruritus preventive or remedy which contains as an active ingredient either a tricyclic compound represented by the following formula (I): I [wherein R1 is hydrogen, (un)substituted lower alkyl, (un)substituted lower alkoxy, or halogeno; X1-X2-X3 is CR5 = CR6-CR7 = CR8, N(O)m = CR6-CR7 = CR8, CR5 = CR6-N(O)m = CR8, CR5 = CR6-CR7 = N(O)m, CR5 = CR6-O, CR5 = CR6-S, O-CR7 = CR8, S-CR7 = CR8, or O-CR7 = N; and Y is -CH2S-, -CH2SO-, -CH2SO2-, -CH2O-, -CH = CH-, -(CH2)p-, -SCH2-, -SOCH2-, -SO2CH2-, or -OCH2-] or a pharmaceutically acceptable salt of the compound This application belongs to the medicinal field.

IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tricyclic compds. as preventives or remedies for pruritus)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:777737 CAPLUS
DN 137:289045
TI Remedies for vesical stimulation in association with prostatauxe
IN Yamagata, Tsuyoshi; Atsuki, Kaoru; Ohno, Tetsuji; Shirakura, Shiro; Karasawa, Akira
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002078712 | A1 | 20021010 | WO 2002-JP3169 | 20020329 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442472 | A1 | 20021010 | CA 2002-2442472 | 20020329 |
| AU 2002244945 | A1 | 20021015 | AU 2002-244945 | 20020329 |
| EP 1380299 | A1 | 20040114 | EP 2002-713257 | 20020329 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 2003003610 | A2 | 20040301 | HU 2003-3610 | 20020329 |
| HU 2003003610 | A3 | 20050228 | | |
| BR 2002008416 | A | 20040302 | BR 2002-8416 | 20020329 |
| CN 1499974 | A | 20040526 | CN 2002-807707 | 20020329 |
| CN 1230178 | C | 20051207 | | |
| JP 4104986 | B2 | 20080618 | JP 2002-576978 | 20020329 |
| US 20040110784 | A1 | 20040610 | US 2003-472148 | 20030922 |
| US 7354949 | B2 | 20080408 | | |
| MX 2003008815 | A | 20040217 | MX 2003-8815 | 20030926 |
| NO 2003004357 | A | 20031124 | NO 2003-4357 | 20030929 |
| IN 2003CN01533 | A | 20051125 | IN 2003-CN1533 | 20030929 |
| HK 1064616 | A1 | 20060413 | HK 2004-107683 | 20041007 |
| PRAI JP 2001-99799 | A | 20010330 | | |
| WO 2002-JP3169 | W | 20020329 | | |

OS MARPAT 137:289045
GI



I

AB Remedies for vesical stimulation in association with prostatauxe which contain as the active ingredient tricyclic compds. represented by the following general formula I (R1 = H, optionally substituted lower alkyl, etc.; X1-X2-X3 = CR5-CR6-CR7=CR8, CR5-CR6-S, etc.; Y = -CH2S-, SOCH2, etc.; and R2 = H, etc.) or pharmacol. acceptable salts thereof.

IT 214764-26-8
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedies for vesical stimulation in association with prostatauxe)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:777736 CAPLUS
DN 137:289044
TI Remedies for vesical hyperesthesia
IN Yamagata, Tsuyoshi; Atsuki, Kaoru; Ohno, Tetsuji; Shirakura, Shiro; Karasawa, Akira
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002078711 | A1 | 20021010 | WO 2002-JP3168 | 20020329 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442468 | A1 | 20021010 | CA 2002-2442468 | 20020329 |
| AU 2002244944 | A1 | 20021015 | AU 2002-244944 | 20020329 |
| EP 1384481 | A1 | 20040128 | EP 2002-713256 | 20020329 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| HU 2003003609 | A2 | 20040301 | HU 2003-3609 | 20020329 |
| HU 2003003609 | A3 | 20051128 | | |
| CN 1498109 | A | 20040519 | CN 2002-806801 | 20020329 |
| BR 2002008412 | A | 20040803 | BR 2002-8412 | 20020329 |
| US 20040106671 | A1 | 20040603 | US 2003-472144 | 20030922 |
| MX 2003008814 | A | 20040217 | MX 2003-8814 | 20030926 |
| NO 2003004358 | A | 20031128 | NO 2003-4358 | 20030929 |
| IN 2003CN01534 | A | 20051125 | IN 2003-CN1534 | 20030929 |
| PRAI JP 2001-99800 | A | 20010330 | | |
| WO 2002-JP3168 | W | 20020329 | | |

OS MARPAT 137:289044
GI



I

AB Remedies for vesical hyperesthesia which contain as the active ingredient tricyclic compds. represented by the following general formula I (R1 = H, optionally substituted lower alkyl, etc.; X1-X2-X3 = CR5-CR6-CR7=CR8, CR5=CR6-S, etc.; Y = -CH2S-, SOCH2, etc.; and R2 = H, etc. ) or pharmacol. acceptable salts thereof.

IT 214764-26-8
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (remedies for vesical hyperesthesia)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:777735 CAPLUS
DN 137:289043
TI Remedies for vesical hyperactivity
IN Yamagata, Tsuyoshi; Atsuki, Kaoru; Ohno, Tetsuji; Shirakura, Shiro; Karasawa, Akira
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002078710 | A1 | 20021010 | WO 2002-JP3167 | 20020329 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2442463 | A1 | 20021010 | CA 2002-2442463 | 20020329 |
| | AU 2002244943 | A1 | 20021015 | AU 2002-244943 | 20020329 |
| | EP 1384480 | A1 | 20040128 | EP 2002-713255 | 20020329 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | HU 2003003608 | A2 | 20040301 | HU 2003-3608 | 20020329 |
| | HU 2003003608 | A3 | 20070628 | | |
| | BR 2002008420 | A | 20040330 | BR 2002-8420 | 20020329 |
| | CN 1498110 | A | 20040519 | CN 2002-806802 | 20020329 |
| | US 20040116459 | A1 | 20040617 | US 2003-472143 | 20030922 |
| | US 7276532 | B2 | 20071002 | | |
| | MX 2003008725 | A | 20040405 | MX 2003-8725 | 20030925 |
| | NO 2003004356 | A | 20031127 | NO 2003-4356 | 20030929 |
| | IN 2003CN01535 | A | 20051125 | IN 2003-CN1535 | 20030929 |
| PRAI | JP 2001-99801 | A | 20010330 | | |
| | WO 2002-JP3167 | W | 20020329 | | |

OS MARPAT 137:289043
GI



I

AB Remedies for vesical hyperactivity which contain as the active ingredient tricyclic compds. represented by the following general formula I (R1 = H, optionally substituted lower alkyl, etc.; X1-X2-X3 = CR5-CR6-CR7=CR8, CR5=CR6-S, etc.; Y = -CH2S-, SOCH2, etc.; and R2 = H, etc.) or pharmacol. acceptable salts thereof.

IT 214764-26-8 214764-36-0
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedies for vesical hyperactivity)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214764-36-0 CAPLUS
CN Propanamide, N-(6-chloro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:777655 CAPLUS
DN 137:273240
TI (S)-N-(5,5-dioxido-10-oxo-4, 10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
IN Yamagata, Tsuyoshi; Atsuki, Kaoro; Ohno, Tetsuji; Shirakura, Shiro; Degroat, William C.; Yoshimura, Naoki; Sculptoreanu, Adrian
PA Kyowa Hakko Kogyo Co., Ltd., Japan; University of Pittsburgh
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2002078633 | A2 | 20021010 | WO 2002-US9575 | 20020329 |
| WO 2002078633 | A3 | 20030724 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2442452 | A1 | 20021010 | CA 2002-2442452 | 20020329 |
| AU 2002338234 | A1 | 20021015 | AU 2002-338234 | 20020329 |
| EP 1372639 | A2 | 20040102 | EP 2002-757832 | 20020329 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| JP 2004529133 | T | 20040924 | JP 2002-576901 | 20020329 |
| US 20040122078 | A1 | 20040624 | US 2003-473348 | 20030930 |
| US 7122173 | B2 | 20061017 | | |
| US 20060276531 | A1 | 20061207 | US 2006-503067 | 20060814 |
| PRAI US 2001-279699P | P | 20010330 | | |
| WO 2002-US9575 | W | 20020329 | | |
| US 2003-473348 | A3 | 20030930 | | |

AB The invention provides an agent, (S)-(N-(5,5-dioxido-10-oxo-4,10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide) for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising measuring a slowly-inactivating A-type K+ channel opening activity as an index.
IT 214764-26-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((S)-N-(5,5-dioxido-10-oxo-4, 10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide for treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:547845 CAPLUS
DN 138:215150
TI Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats
AU Lu, Shing-Hwa; Yamagata, Tsuyoshi; Atsuki, Kaoru; Sun, Lushen; Smith, Christopher P.; Yoshimura, Naoki; Chancellor, Michael B.; de Groat, William C.
CS Department of Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA
SO Brain Research (2002), 946(1), 72-78
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
AB The effects of KW-7158, a putative afferent nerve inhibitor, on reflex bladder activity and vesico-vascular reflexes were evaluated in urethane anesthetized SD rats with normal and xylene-irritated bladders. The bladder was filled with saline until the appearance of large amplitude spontaneous bladder contractions (LA-BC). Vesico-vascular reflexes were measured as increases in systolic arterial blood pressure during LA-BC or when the bladder was distended by a range of pressures. In normal rats, KW-7158 (10 and 100 μg/kg, i.v.) did not alter the amplitude or volume threshold for inducing LA-BC but increased the intercontraction interval. After xylene-irritation, which decreased volume threshold and intercontraction interval and induced small amplitude bladder contractions, KW-7158 increased volume threshold (65%) and intercontraction interval (150%) and decreased the number of small amplitude bladder contractions. Vesico-vascular reflexes induced during LA-BC or by bladder distension were suppressed (19.4-100%) by KW-7158. The effect of KW-7158 to depress vesico-vascular reflexes as well as xylene-induced bladder hyperactivity without altering the amplitude of contractions is consistent with the view that the drug affects reflex bladder activity at least in part by depressing afferent pathways.
IT 214764-26-8, KW 7158
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats)
RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:129132 CAPLUS
DN 136:183808
TI Method for preparation of 9-amino-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one derivatives via Friedel-Crafts cyclization of 2-(3-thienylmethylthio)benzoic acid derivatives .
IN Imai, Eiichiro; Mimura, Takashi; Matsushita, Tetsuo; Mori, Shinichiro; Ogasa, Takehiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI JP 2002053580 | A | 20020219 | JP 2000-241112 | 20000809 |
| PRAI JP 2000-241112 | | 20000809 | | |

OS CASREACT 136:183808; MARPAT 136:183808
GI



I



II



III

AB The title compds. [I; X = H, (un)substituted lower alkyl or alkoxy, halo; Y = H, (un)substituted lower alkyl or alkenyl, CF3, (un)substituted lower alkoxy, NH2, (un)substituted mono- or di(lower alkyl)amino, (un)substituted aryl, heteroaryl, aralkyl, arylamino, or alicyclic heterocyclyl, (CH2)nCP1(P2)Q; wherein n = 0, 1; P1, P2 = H, (un)substituted lower alkyl, cycloalkyl, aryl, or aralkyl, CF3; or P1 and P2 are combined together to form cycloalkyl; Q = HO, (un)substituted lower alkoxy, NH2, halo] are prepared by Friedel-Crafts reaction of 2-(3-thienylmethylthio)benzoic acid derivs. (II; R1 = halo, NO2; X = same as above) or salts thereof for cyclization to give 4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one derivs. (III; R1, X = same as above). This process is industrially suitable and readily gives in high yields the compds. I which are useful as therapeutic agents for urinary incontinence (no data). Thus, chlorination of 3-thiophenemethanol by SOCl2 in at room temperature for 1 h in toluene followed washing with 1.27 M aqueous NaOH gave a toluene solution of 3-chloromethylthiophene which was stirred with 2-fluoro-6-mercaptobenzoic acid and aqueous NaOH at 40° for 1 h to give 89% 2-fluoro-6-(3-thienylmethylthio)benzoic acid (IV). A toluene solution of IV was treated dropwise with trifluoroacetic anhydride under ice-cooling and stirred at the same temperature for 1 h and then at 40° for 1 h to give 85% 9-fluoro-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one which was heated with benzylamine under stirring at 80° for 6 h

to give 96% 9-benzylamino-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one (V). An EtOAc solution of V was treated with an EtOAc solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone at 40° and stirred at the same temperature for 2 h to give 87% 9-amino-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one (VI). A solution of (S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoic acid was treated with SOCl2 at -15° and stirred at -15° to -5° for 1 h, followed by adding VI, and the resulting mixture was stirred at room temperature overnight to give 63% (S)-9-[(3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino]-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one which was oxidized by m-chloroperbenzoic acid in CH2Cl2 at room temperature for 3 h to give (S)-5,5-dioxo-9-[(3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino]-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one.

IT 214764-26-8P, (S)-5,5-Dioxo-9-[(3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl)amino]-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method for preparation of 9-aminodihydrothieno[c][1]benzothiepinone derivs. via Friedel-Crafts cyclization of (3-thienylmethylthio)benzoic acid derivs.)

RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:240151 CAPLUS
DN 134:261274
TI Tricyclic compounds for the treatment of polIakiuria and urinary incontinence, pharmaceutical compositions, and preparation thereof
IN Yoshida, Makoto; Seishi, Takashi; Aono, Shigeru; Yamagata, Tsuyoshi; Atsuki, Kaoru; Kumazawa, Toshiaki; Takai, Haruki; Suzuki, Koji; Karasawa, Akira
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO U.S., 30 pp., Cont.-in-part of PCT Appl. WO98JP01713.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI US 6211227 | B1 | 20010403 | US 1999-417626 | 19991014 |
| WO 9846587 | A1 | 19981022 | WO 1998-JP1713 | 19980415 |
| W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| PRAI JP 1997-97233 | A | 19970415 | | |
| WO 1998-JP1713 | A2 | 19980415 | | |

OS MARPAT 134:261274
GI



I

AB Tricyclic compds. are provided which are useful for the treatment of pollakiuria and urinary incontinence and which are represented by I [R1 = H, (un)substituted lower alkyl, etc.; X1X2X3 = C(R5):C(R6)C(R7):CR8; (R5-R8 = H, (un)substituted lower alkyl, OH, (un)substituted lower alkoxy, etc.), N(O)m:C(R5)C(R6):C(R7) (R5-R7 as above; m = 0, 1), SC(R7):C(R8) (R7, R8 as above), etc.; when R2 is H, (un)substituted lower alkyl, (un)substituted lower alkoxy, (un)substituted N-substituted heterocyclyl, (CH2)nC(Q)(R3)(R4) (n = 0, 1; R3, R4 = H, (un)substituted lower alkyl, CF3, etc., or R3 and R4 may be combined to form cyclic alkyl; Q = OH, halogen, etc.), etc.; Y = CH2SO2, SCH2, SOCH2, SO2CH2, etc.] and pharmaceutically acceptable salts thereof.
IT 214763-95-8P 214764-26-8P 214764-27-9P
214764-29-1P 214764-30-4P 214764-34-8P
214764-36-0P 214764-38-2P 332029-02-4P
332029-03-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tricyclic compound preparation for treatment of polIakiuria and urinary incontinence)
RN 214763-95-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-26-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214764-27-9 CAPLUS
CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214764-29-1 CAPLUS
CN Propanamide, N-(4,10-dihydro-6-methoxy-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-30-4 CAPLUS
CN Propanamide, N-(4,10-dihydro-6-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-34-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-8-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-36-0 CAPLUS
CN Propanamide, N-(6-chloro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-38-2 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-(6-fluoro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 332029-02-4 CAPLUS
CN Propanamide, N-(4,10-dihydro-2-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 332029-03-5 CAPLUS
CN Propanamide, N-(4,10-dihydro-3-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:708807 CAPLUS
DN 129:316211
OREF 129:64531a,64534a
TI Preparation of tricyclic heterocyclic compounds for the treatment of pollakiuria and enuresis
IN Yoshida, Makoto; Seishi, Takashi; Aono, Shigeru; Takai, Haruki; Suzuki, Koji; Yamagata, Tsuyoshi; Atsuki, Kaoru; Karasawa, Akira; Kumazawa, Toshiaki
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9846587 | A1 | 19981022 | WO 1998-JP1713 | 19980415 |
| | W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2286723 | A1 | 19981022 | CA 1998-2286723 | 19980415 |
| | CA 2286723 | C | 20070130 | | |
| | AU 9868515 | A | 19981111 | AU 1998-68515 | 19980415 |
| | AU 738757 | B2 | 20010927 | | |
| | EP 979821 | A1 | 20000216 | EP 1998-914022 | 19980415 |
| | EP 979821 | B1 | 20060913 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| | BR 9808552 | A | 20000523 | BR 1998-8552 | 19980415 |
| | HU 2000002461 | A2 | 20010628 | HU 2000-2461 | 19980415 |
| | HU 2000002461 | A3 | 20030128 | | |
| | JP 3283267 | B2 | 20020520 | JP 1998-543737 | 19980415 |
| | CN 1260220 | C | 20060621 | CN 1998-804964 | 19980415 |
| | AT 339409 | T | 20061015 | AT 1998-914022 | 19980415 |
| | ES 2273413 | T3 | 20070501 | ES 1998-914022 | 19980415 |
| | NO 9904960 | A | 19991209 | NO 1999-4960 | 19991012 |
| | US 6211227 | B1 | 20010403 | US 1999-417626 | 19991014 |
| | HK 1025572 | A1 | 20070427 | HK 2000-104846 | 20000802 |
| PRAI | JP 1997-97233 | A | 19970415 | | |
| | WO 1998-JP1713 | W | 19980415 | | |

OS MARPAT 129:316211
GI




I




II

AB Tricyclic compds. of general formula (I) and pharmacol. acceptable salts thereof [wherein R1 is hydrogen, halo, substituted or unsubstituted lower alkyl or alkoxy; X1-X2-X3 is CR5:CR6CR7:CR8 (wherein R5, R6, R7 and R8 are each independently hydrogen, substituted or unsubstituted lower alkyl, hydroxyl, substituted or unsubstituted lower alkoxy or the like), N(O)m:CR5CR6CR7 (wherein R5, R6 and R7 are each the same as defined above; and m is 0 to 1), SCR7:CR8 (wherein R7 and R8 are each the same as defined above) or the like; R2 is hydrogen, substituted or unsubstituted lower

alkyl, substituted or unsubstituted lower alkoxy, a substituted or unsubstituted N-substituted heterocyclic group or a group of general formula (CH2)nC(Q)R3R4; (wherein n is 0 or 1; R3 and R4 are each independently hydrogen, substituted or unsubstituted lower alkyl, trifluoromethyl or the like, or alternatively R3 and R4 may be united to form cyclic alkyl and Q is hydroxyl, halogeno or the like); and Y is CH2SO2, SCH2, SOCH2, SO2CH2 or the like] are prepared Thus, 3,3,3-trifluoro-2-hydroxy-2-methylpropanoic acid was stirred with SOCl2 in dimethylacetamide at .apprx.-15° to .apprx.5° for 1 h and the condensed with 9-amino-4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one at room temperature overnight followed by oxidation with m-chloroperbenzoic acid in CH2Cl2 to give the title compound, 4,10-dihydrothieno[3,2-c][1]benzothiepin-10-one derivative (II; X = H). II (X = H) and II (X = Cl) in vitro inhibited the KCl (15 mmol/L)-induced contraction of rat bladder muscle strips with IC50 of 2.6 and 0.7 μM, resp., and in vivo prolonged the contraction intervals of rat bladder by 203±21and 148±3%, resp., 5 h after the administration of these compds.

IT 214763-95-8P 214764-26-8P 214764-27-9P
214764-29-1P 214764-30-4P 214764-34-8P
214764-36-0P 214764-38-2P 214764-51-9P
214764-52-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic heterocyclic compds. for treatment of pollakiuria and enuresis)

RN 214763-95-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-26-8 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214764-27-9 CAPLUS

CN Propanamide, N-(4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-

c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214764-29-1 CAPLUS
CN Propanamide, N-(4,10-dihydro-6-methoxy-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-30-4 CAPLUS
CN Propanamide, N-(4,10-dihydro-6-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-34-8 CAPLUS
CN Propanamide, N-(4,10-dihydro-8-methyl-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-36-0 CAPLUS
CN Propanamide, N-(6-chloro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-38-2 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-(6-fluoro-4,10-dihydro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 214764-51-9 CAPLUS
CN Propanamide, N-(4,10-dihydro-2-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 214764-52-0 CAPLUS
CN Propanamide, N-(4,10-dihydro-3-nitro-5,5-dioxido-10-oxothieno[3,2-c][1]benzothiepin-9-yl)-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his full

     (FILE 'HOME' ENTERED AT 19:52:11 ON 21 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 19:52:22 ON 21 MAR 2009
L1             STRUCTURE UPLOADED
               D
L2              0 SEA SSS SAM L1
L3             16 SEA SSS FUL L1
                  D QUE L3 STAT
                  D 1-16 IDE CAN

     FILE 'CAPLUS' ENTERED AT 19:54:04 ON 21 MAR 2009
L4             20 SEA ABB=ON  PLU=ON  L3
                  D 1-20 BIB ABS HITSTR


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   20 MAR 2009  HIGHEST RN 1124448-78-7
     DICTIONARY FILE UPDATES:  20 MAR 2009  HIGHEST RN 1124448-78-7

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 21 Mar 2009  VOL 150 ISS 13
     FILE LAST UPDATED: 20 Mar 2009  (20090320/ED)

     Caplus now includes complete International Patent Classification (IPC)
     reclassification data for the third quarter of 2008.

     CAS Information Use Policies apply and are available at:

     http://www.cas.org/legal/infopolicy.html

     This file contains CAS Registry Numbers for easy and accurate
     substance identification.

=> log y
```

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 115.80 | 340.14 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -16.40 | -16.40 |

STN INTERNATIONAL LOGOFF AT 19:57:31 ON 21 MAR 2009